Abbott Labs 2nd-quarter revenues rise 1.9%
US health care company Abbott Laboratories (NYSE: ABT), which since its spin-out of its research-based prescription medicines business into AbbVie, now makes infant formula like Similac as well as medical devices and drugs, posted second-quarter 2014 financial results were much in line with expectations.
Abbott reported $5.6 billion in second quarter revenue, a 1.9% increase over the prior-year period and just beating the $5.5 billion Wall Street forecast. Net income came in at $466 million, or $0.30 per share, results that are slightly down (-2.1%) from earnings of $476 million, or $0.30 posted in the like quarter of 2013. Excluding special items, including a $369 million after-tax charge related to cost-savings initiatives, Abbott’s profit came in at $829 million, or $0.54 per share, beating the $0.51 per-share consensus forecasts from analysts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze